Consensus Cloud Solutions, Inc. CCSI 深 沪
等待开盘 11-10 09:30:00 美东时间
42.87
-0.280
-0.65%
华盛通- 最 高45.15
- 今 开43.58
- 成交量 34.66万股
- 最 低 42.40
- 昨 收 43.15
- 总市值 7.63亿
- 52周最高 45.15
- 市盈率 静 9.86
- 换手率 1.95%
- 52周最低 20.20
- 委 比 22.70%
- 总股本 1780.74万
- 历史最高 69.31
- 量 比 1.94
- 振 幅 6.37%
- 历史最低 11.62
- 每 手 1
- 风险率 6.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Consensus Cloud Solns Q3 2026 Earnings Call Transcript
Consensus Cloud Solns (NASDAQ:CCSI) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.be...
11-06 06:37
美股大行评级 | Meta获4家机构看好！目标价最高升至950美元；好市多绩后齐遭机构降低目标价
今日重点评级关注：古根海姆：维持Damora Therapeutics"买入"评级，目标价从40美元升至60美元；HC Wainwright & Co.：维持Rezolute"买入"评级，目标价从5美元升至10美元
09-28 12:37
BTIG Reiterates Buy on Consensus Cloud Solns, Maintains $50 Price Target
BTIG analyst David Larsen reiterates Consensus Cloud Solns (NASDAQ:CCSI) with a Buy and maintains $50 price target.
09-25 17:56
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
BTIG Maintains Buy on Consensus Cloud Solns, Raises Price Target to $50
BTIG analyst David Larsen maintains Consensus Cloud Solns (NASDAQ:CCSI) with a Buy and raises the price target from $45 to $50.
08-10 17:37
美股大行评级 | 最高120美元！大小摩等7家大行集体上调英特尔目标价；汇丰首予SpaceX"持有"评级，目标价115美元
今日重点评级关注：HC Wainwright & Co.：维持居里"买入"评级，目标价从17美元升至43美元；花旗：维持Klaviyo"买入"评级，目标价从31美元升至34美元
07-27 14:02
BTIG Maintains Buy on Consensus Cloud Solns, Raises Price Target to $45
BTIG analyst David Larsen maintains Consensus Cloud Solns (NASDAQ:CCSI) with a Buy and raises the price target from $40 to $45.
07-24 18:26
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Oppenheimer Maintains Outperform on Consensus Cloud Solns, Raises Price Target to $35
Oppenheimer analyst Ian Zaffino maintains Consensus Cloud Solns (NASDAQ:CCSI) with a Outperform and raises the price target from $32 to $35.
05-13 01:37
Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday
US stocks, including Monster Beverage Corp, rose on Friday. Monster Beverage reported better-than-expected financial results, causing a 12.8% jump in their shares.
05-08 22:15
